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Studies on cardiovascular safety in cancer patients treated with highly or moderately emetogenic chemotherapy (HEC or MEC),
who may have taken the antiemetic, aprepitant, have been limited to clinical trials and postmarketing spontaneous reports.
Our study explored background rates of cardiovascular disease (CVD) events among HEC- or MEC-treated cancer patients in
a population-based setting to contextualize events seen in a new drug development program and to determine at a high level
whether rates diﬀered by aprepitant usage. Medical and pharmacy claims data from the 2005–2007 IMPACT National Benchmark
Database were classiﬁed into emetogenic chemotherapy categories and CVD outcomes. Among 5827 HEC/MEC-treated patients,
frequencies were highest for hypertension (16–21%) and composites of venous (7–12%) and arterial thromboembolic events (4–
7%).Aprepitant usersgenerally didnot experience higher frequencies of events compared to nonusers.Our studyserves asa useful
benchmark of background CVD event rates in a population-based setting of cancer patients.
1.Background/Objective
Chemotherapy-induced nausea and vomiting (CINV) neg-
atively impacts the quality of life in cancer patients [1]
and may lead to nonadherence to or dose reductions in
chemotherapy [2]. Potential cardiac eﬀects of antiemetics
warrantspecialattention,givenanestimated13–60%burden
of cardiovascular-related diseases that increases with age,
among cancer patients [3–5]. Cardiovascular disease (CVD)
can be preexisting, a result or natural progression of the
malignancy or an adverse event resulting from chemother-
apeutic treatment, such as anthracyclines and alkylating
agents [6, 7]. For example, cyclophosphamide treatment has
been associated with a 7–28% incidence of heart failure, cis-
platin has been associated with an 8.5% incidence of venous
thromboembolism, including deep vein thrombosis and pul-
monary embolism [8], and doxorubicin/daunorubicin has
been associated with 0.5–3% incidence of arrhythmias [9].
Aprepitant is currently the only FDA-approved neu-
rokinin (NK1) receptor antagonist (RA) that, when coad-
ministered with other antiemetics, such as corticosteroids
(dexamethasone) and serotonin 5-HT3 receptor antagonists
(e.g., dolasetron, granisetron, ondansetron, and palonoset-
ron), augments the prevention of acute and, particularly,
delayed CINV [10]. Although aprepitant has been shown to
begenerallywelltoleratedinclinicaltrials[11],isolatedcases
ofseriousadverseevents,suchasbradycardia[12]andhyper -
tension [13], have been reported in two highly emetogenic
chemotherapy (HEC) studies comparing aprepitant plus
ondansetron and dexamethasone to the standard regimen
of ondansetron and dexamethasone, alone [14, 15]. Other
cardiovascular events (>0.5% and greater than standard
therapy), regardless of causality, have also been reported in
patientstreatedwiththeaprepitantregimenineitherHECor
MEC studies, including myocardial infarction, tachycardia,2 Journal of Cancer Epidemiology
Table 1: Characteristics of 5827 patients with select∗ cancers and ≤4 cycles of HEC, MEC, or HEC/MEC combined, 2005–2007 IMPACT
National Benchmark Database (OptumInsight, Eden Prairie, MN).
Characteristic
HEC and/or MEC HEC only MEC only HEC/MEC combined
(N = 5827) (N = 330) (N = 5269) (N = 228)
Total No
Aprep Aprep Total No
Aprep Aprep Total No
Aprep Aprep Total No
Aprep Aprep
% Male 21.90 27.56 11.14 45.45 52.73 38.18 19.57 25.59 7.52 41.67 47.48 32.58
% Female 78.10 72.44 88.86 54.55 47.27 61.82 80.43 74.41 92.48 58.33 52.52 67.42
Mean age (yrs) 54.7 56.3 51.7 54.8 55.8 53.8 54.6 56.2 51.4 56.2 57.1 54.8
%A g e≥60 32.52 38.22 21.69 35.15 38.79 31.52 32.23 38.29 20.10 35.53 35.97 34.83
%A g e≥65 14.35 18.31 6.82 14.85 16.97 12.73 14.22 18.33 5.98 16.67 19.42 12.36
% Breast cancer 60.41 50.98 78.31 26.67 19.39 33.94 64.07 53.74 84.74 24.56 18.71 33.71
% Colorectal cancer 7.00 9.30 2.64 6.97 6.67 7.27 6.95 9.45 1.94 8.33 8.63 7.87
% Head and neck
cancer 5.85 5.74 6.07 26.97 26.67 27.27 3.93 4.18 3.42 19.74 20.14 19.10
% Lung cancer 25.73 32.91 12.09 36.67 44.85 28.48 24.05 31.51 9.11 48.68 53.96 40.45
% Ovarian cancer 5.59 6.47 3.93 6.67 7.27 6.06 5.60 6.55 3.70 3.95 3.60 4.49
% Prior history of
CVD‡ 50.76 55.28 42.19 61.52 64.85 58.18 49.86 54.68 40.21 56.14 58.99 51.69
∗Breast, colorectal, head and neck, lung, and ovarian cancers.
‡Prior history of CVD is deﬁned as a diagnosis of any of the following prior to the start of HEC and/or MEC: hypertension, diabetes, coronary artery disease,
myocardial infarction, congestive heart failure, stroke, transient ischemic attack, deep vein thrombosis (DVT), and pulmonary embolism (PE).
Note: percentage by type of cancer may add to >100% due to patients having multiple cancer types.
deep vein thrombosis, ﬂushing, hypertension, and hypoten-
sion[12].However,resultsfromclinicaltrialsmaynotreﬂect
those observed in clinical practice, and population-based
studies of the cardiovascular eﬀects of aprepitant are lacking.
We aimed to quantify background rates of several CVD-
related events among HEC and/or MEC-treated cancer
patients for two purposes: to understand expected rates
amongcancerpatientsinordertocontextualizeeventswhich
may be seen in our clinical development program of a
similar patient population with a similar drug and to further
understand at a high level whether rates diﬀered by the
decision to treat with aprepitant, recognizing that users
versus nonusers may diﬀer with respect to disease severity,
access to care, preexisting conditions, and other factors.
Therefore, the objective of this study was to use a large,
US healthcare claims database to assess the frequency of
CVD-relatedeventsamongHECand/orMEC-treatedcancer
patients and to determine if the frequency was impacted by
the decision to treat with aprepitant.
2. Methods
A retrospective cohort study of adult patients with select
cancers,treatedwithHECand/orMEC,wasconductedusing
2005–2007 data from the IMPACT National Benchmark
Database (OptumInsight, Eden Prairie, MN), a comprehen-
sive, deidentiﬁed healthcare claims database that is repre-
sentative of the nonelderly, insurance-carrying population in
the United States. At the time of our analysis, the database
contained inpatient/outpatient and pharmacy claims, a sub-
set of lab results and enrolment information on over 82
million members from 45 healthcare plans serving nine
census regions from 1997 to 2007. The IMPACT database
is HIPAA compliant and features encrypted member and
provider IDs.
The study included several cancer types commonly
treated with HEC or MEC, namely, breast, colorectal, head
and neck, lung, and ovarian cancer patients (Table 4), in
adults with ≤4 cycles of HEC and/or MEC as documented
in one or more claims in the year 2006. We choose ≤4
cycles because two-thirds of all treated patients had up to
and including 4 cycles. The study analysis period was deﬁned
as the ﬁrst day of the ﬁrst HEC and/or MEC cycle to 30
days past the ﬁrst day of the last cycle. The start of a new
cycle of chemotherapy was deﬁned by a period of more than
7 days but less than 45 days between cycles. The start of
treatment was the ﬁrst HEC and/or MEC claim in 2006, with
3 months prior with no claim (“wash-in” period) to ensure
thattherewasnoCVDeﬀectofHEC/MECtreatmentin2005
that was carried over into 2006. The end of treatment was
reached after 45 days of no additional HEC and/or MEC
claim following the last claim (“wash-out” period) to ensure
that all CVD eﬀects from HEC/MEC treatment in 2006 were
captured. To illustrate, for patients whose ﬁrst HEC or MEC
claim was between January 1, 2006 and March 31, 2006, the
enrolment criteria for inclusion in the study extended as far
backasOctober1,2005.Forpatientswhoselastclaimin2006
wasseenafterDecember1,2006,enrolmentinto2007tolook
for further treatment and the 45 day “wash-out” period was
required.
Data on aprepitant exposure and chemotherapy was ob-
tained from the inpatient/outpatient and pharmacy claims.
Chemotherapeutic agents were deﬁned as HEC if they were
associated with >90% of treated patients having emesis, andJournal of Cancer Epidemiology 3
Table 2: Cardiovascular-related events in 5827 patients with select∗ cancers and ≤4 cycles of HEC, MEC, or HEC/MEC combined, 2005–
2007 IMPACT National Benchmark Database (OptumInsight, Eden Prairie, MN).
Cardiovascular and
thromboembolic events
HEC and/or MEC HEC only MEC only HEC plus MEC
(N = 5827) (N = 330) (N = 5269) (N = 228)
n % n % n % n %
Angina pectoris 32 0.55 3 0.91 28 0.53 1 0.44
Arterial disorder 9 0.15 2 0.61 7 0.13 0 —
Arterial occlusive disease 2 0.03 0 — 2 0.04 0 —
Arterial thromboembolic
(excluding chest pain/discomfort) 254 4.36 23 6.97 220 4.18 11 4.82
Arterial thromboembolic
(including chest pain/discomfort) 881 15.12 72 21.82 754 14.31 55 24.12
Cardiac arrest 25 0.43 4 1.21 19 0.36 2 0.88
Cardiac disorder 3 0.05 0 — 3 0.06 0 —
Cardio-respiratory arrest 27 0.46 4 1.21 21 0.40 2 0.88
Cardiogenic shock 1 0.02 0 — 1 0.02 0 —
Cerebral ischemia 62 1.06 8 2.42 53 1.01 1 0.44
Cerebrovascular accident 52 0.89 3 0.91 49 0.93 0 —
Chest pain or discomfort 719 12.34 62 18.79 610 11.58 47 20.61
Circulatory collapse 14 0.24 1 0.30 13 0.25 0 —
Embolism 97 1.66 8 2.42 83 1.58 6 2.63
Hypertension 966 16.58 68 20.61 854 16.21 44 19.30
Hypotension 149 2.56 11 3.33 126 2.39 12 5.26
Iliac artery embolism 2 0.03 1 0.30 1 0.02 0 —
Increased platelets 7 0.12 0 — 7 0.13 0 —
Intermittent claudication 9 0.15 2 0.61 4 0.08 3 1.32
Myocardial infarction 11 0.19 1 0.30 10 0.19 0 —
Myocardial ischemia 11 0.19 0 — 11 0.21 0 —
Peripheral embolism 38 0.65 4 1.21 30 0.57 4 1.75
P e r i p h e r a l i s c h e m i a — — 0—0—0—
S u d d e n d e a t h — — 0—0—0—
Syncope 140 2.40 12 3.64 117 2.22 11 4.82
Venous thromboembolic 450 7.72 40 12.12 383 7.27 27 11.84
∗Breast, colorectal, head and neck, lung, and ovarian cancers.
MEC, if associated with 30–90% of patients having emesis
(Table 5). Chemotherapies were classiﬁed by a physician
within our department using previously published criteria
as guidance [16, 17]. Cardiovascular outcomes of interest
included arterial and venous thromboembolic events, indi-
vidually as well as a composite event, as well as cardiac arrest,
hypertension, hypotension, increased platelets, sudden
death,andsyncope(Table 4).Patientcharacteristicsincluded
gender, age, tumor type, and prior history of cardiovascular
disease. Prior CVD was deﬁned as the presence of a claim for
hypertension, diabetes, coronary artery disease, myocardial
infarction, congestive heart failure, ischemic stroke, tran-
sient ischemic attack, deep vein thrombosis, or pulmonary
embolism anytime before HEC or MEC initiation.
Subjects who used either HEC or MEC were categorized
into 3 emetogenic chemotherapy groups: HEC-only, MEC-
only, or HEC/MEC combined. All analyses, including the
distribution (% or mean) of patient characteristics and
the frequency of CVD outcomes of interest, were tabulated
overall and stratiﬁed by aprepitant usage and emetogenic
category of chemotherapy. Analyses were not further strat-
iﬁed by number of chemotherapy cycles, however, due to
insuﬃcient sample size. This study was purely descriptive,
and therefore, no formal statistical comparison was made
between aprepitant users and nonusers. Rather, the data
was visually inspected for noteworthy absolute diﬀerences of
≥5% or relative diﬀerences of ≥1.5 times.
3. Results
The number of cancer patients with the cancer types of
interest who had at least 3 months of continuous enrolment
and pharmacy beneﬁt, at least one HEC or MEC claim,
and ≤4 cycles of chemotherapy was 5827. Among these
patients, the distribution of patients by cancer type was
60.4% with breast, 25.7% with lung, 7.0% with colorectal,4 Journal of Cancer Epidemiology
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Table 4: ICD-9 codes for selected cancers and cardiovascular-relat-
ed events.
Cancer ICD-9-CM code(s)
Breast 174.0-174.6, 174.8, 174.9,
175, 175.0, 175.9
Colorectal
153, 153.0-153.9, 154,
154.0-154.3, 154.8,
230.3-230.6
Head and neck
140.0-140.9, 141.0-141.9,
142.0-142.9, 143.0-143.9,
144.0-144.9, 145.0-145.9,
146.0-146.9, 147.0-147.9,
148.0-148.9, 149.0-149.9,
161.0-161.9
Lung 162.2-162.5, 162.8, 162.9
Ovarian 183.0
CVD-related events ICD-9-CM code(s)
Arterial Thromboembolic events
Angina pectoris 413.x
Arterial disorder 459.9
Arterial occlusive disease 362.34
Cardiac disorder 997.1
Cardio-respiratory arrest 427.5, 799.1
Cardiogenic shock 785.51
Cerebral ischemia 435, 435.8, 435.9, 437.1
Cerebrovascular accident 436, 437
Chest pain or discomfort 586.5x
Circulatory collapse 785.5, 785.50
Embolism
433, 434.x, 444.0–444.2,
444.21, 444.22, 444.81,
444.89, 444.9, 445, 445.01,
445.02, 445.81, 445.89
Iliac artery embolism 444.81
Intermittent claudication 440.21
Myocardial infarction 410.x
Myocardial ischemia 414.8
Peripheral embolism 444.x
Peripheral ischemia 414
Cardiac Arrest 427.5
Hypertension 401.x, 405.x, 401.0, 401.1,
401.9, 796.2
Hypotension 458.x
Increased platelets 238.71, 287.1
Sudden death 798, 798.2
Syncope 780.0, 780.2, 780.9
Venous thromboembolic events
Deep vein thrombosis
451.1, 451.11, 451.19,
451.2, 451.81, 451.83,
451.84, 453.1–453.4,
453.41, 453.42, 453.8, 453.9
Phlebitis 451.x
Phlebitis superﬁcial 451.1
Table 4: Continued.
CVD-related events ICD-9-CM code(s)
Pulmonary embolism 415.1, 415.11, 415.12,
415.19
Superior vena cava occlusion 459.2, 901.2, 38.8
Thrombophlebitis 451.x4
Thrombophlebitis superﬁcial 451.0, 451.82, 671.2x
Varicophlebitis 454.1, 454.2, 454.8
Vena cava thrombosis 453.2
Venous thrombosis 453.0, 453.4, 453.9
5.9% with head and neck, and 5.6% with ovarian cancer
(Table 1). Over 90% of patients had treatment by MEC-
only, followed by 5.7% with HEC-only and 3.9% with both
HEC and MEC. Females comprised the majority across
chemotherapy groups (55% HEC-only; 80% MEC-only;
58% HEC/MEC combination), and this gender diﬀerence
was greater among those who took aprepitant compared to
those who did not. The mean age (∼55 years) was similar
across the chemotherapy groups, as was the percentage aged
60 years or older. Those taking aprepitant, however, were
2 to 4.8 years younger, on average, and comprised fewer
patients aged 60+ years compared to those who did not
take aprepitant. In HEC-only patients, 32% of aprepitant
users were 60+ compared to 39% of nonusers; in MEC-only
patients, the percentages were 20% versus 38%, respectively;
and in the HEC/MEC combination group, the percentages
were 35% versus 36%, respectively. Using a more traditional
cutpoint of age 65+ years, similar results were found with
aprepitantusershavingasmallerproportionofolderpatients
than nonusers. Over half of patients had a history of CVD
before their chemotherapy treatment, with the HEC-only
group having a higher burden (62%) compared to the MEC-
only group (50%) and HEC/MEC combined group (56%).
The proportion with a prior history of CVD was lower in
aprepitant users compared to nonusers.
Overall, the frequencies of cardiovascular and throm-
boembolic-related events following any HEC or MEC treat-
ment were mostly driven by the MEC-only treatment group,
comprising 90% of patients (Table 2). There were no sudden
deaths. The frequencies of increased platelets, arterial disor-
der, arterial occlusive disease, cardiac disorder, cardiogenic
shock, iliac artery embolism, intermittent claudication and
peripheral ischemia were low (n ≤ 10) in this cohort.
Hypertension occurred in 16% of the MEC-only chem-
otherapy group and was slightly higher among the smaller
HEC-only and HEC/MEC combination groups. Chest pain
or discomfort occurred in 12% of the MEC-only patients,
in 19% of HEC-only patients, and in 21% of combined
HEC/MEC patients. All other single adverse CVD events
occurred at a frequency less than 5%, including MI and
cerebrovascular accident, with the exception of hypotension,
which occurred in 5.3% of those treated with HEC/MEC
combined. The composite measure for arterial thromboem-
bolic events, excluding chest pain and discomfort, ranged
from4%amongtheMEC-onlygroupto7%intheHEC-only6 Journal of Cancer Epidemiology
group. The composite of venous thromboembolic events was
12% for the HEC-only and the HEC/MEC combined groups
and 7% for the MEC-only group.
Stratiﬁed by the decision to include aprepitant in the
antiemetic regimen (Table 3), the analysis demonstrated
that in the MEC-only treated group, the composite of
arterial thromboembolic events (without chest pain and dis-
comfort), cardiac arrest, cardiorespsiratory arrest, cerebral
ischemia, cerebrovascular accident, embolism, hypotension,
and hypertension were more frequent (≥1.5 times or ≥5%
absolute diﬀerence) among those who did not use aprepitant
comparedtothosewhodid.Thoughbasedonsmallnumbers
(n ≤ 10), nonusers also had a higher rate of circulatory
collapse (10 versus 3), increased platelet (6 versus 1), inter-
mittentclaudication(3versus1),andmyocardialischemia(9
versus 2). In all but two events (arterial disorder and arterial
occlusive disorder) of the CVD-related categories among the
MEC-only treated group, the frequency of CVD events was
lower among aprepitant users versus nonusers.
For the HEC-only and the combined HEC/MEC
chemotherapy groups, the numbers of individual cardiovas-
cular-related events were generally too small (n ≤ 10) to
makereliablecomparisonsacrossaprepitantstatus.However,
where cells sizes were larger, HEC-only-treated patients who
did not use aprepitant compared to users had a higher fre-
quency of chest pain/discomfort as a diagnosis, a composite
diagnosis of arterial thromboembolic events, excluding chest
painanddiscomfort,hypertension,andacompositemeasure
of venous thromboembolic events. Though rare (n ≤ 10),
additional events that were more frequent among nonusers
compared to aprepitant users included angina pectoris (2
cases versus 1), embolism (5 versus 3), and hypotension (7
versus4);incontrast,aprepitantusershadahigherfrequency
of syncope (4 cases versus 8) than nonusers.
Among patients treated with both HEC and MEC, there
was a higher frequency of chest pain and discomfort as a
diagnosis and a composite diagnosis of arterial thromboem-
bolic events, including chest pain, in nonusers of aprepitant
compared to users. Users had a higher frequency of hypoten-
sion (6 cases versus 6), intermittent claudication (2 versus 1),
and peripheral embolism (2 versus 2).
4. Discussion
The proportion of patients with CVD events was low (≤5%)
for many events across all chemotherapy groups, except
for hypertension and the composite measures for arterial
thromboembolic and venous thromboembolic events. This
is in line with population-based data showing an annual
incidence (per 1000 persons) of myocardial infarction of
about 4 for men and 2 for women (Atherosclerosis Risk
In Communities Surveillance data, 1987–2001), an annual
incidence (per 1000 persons) of angina pectoris of 4 to over 8
amongmenages45–54and65+years,respectively,and0.9to
over 4 among women ages 45–54 and 65+ years, respectively
(National Heart, Lung, and Blood Institute data, 2006), and
a 33.6% prevalence of hypertension among US adults 20
years and older (National Health and Nutrition Examination
Survey data, 2003–2006) [18].
CVD occurrences were slighter higher for those treated
with HEC only or HEC/MEC combined than those treated
withMEC-only.Inaddition,theHEC/MECcombinedgroup
experienced a slightly elevated frequency of hypotension
compared to the HEC-only or MEC-only groups. It is note-
worthy that sample sizes for the HEC-only and HEC/MEC
combination groups are orders of magnitude smaller than
the MEC-only group, and, thus, slightly higher percentages
observed in these two groups may be due to sample variabil-
ity.
Those who did not use aprepitant compared to those
who did generally experienced higher frequencies of certain
CVD-related events, namely, cardiac arrest, hypertension,
hypotension, the composite of arterial thromboembolic
events without chest pain/discomfort, and, in particular,
cardio-respiratory arrest, cerebral ischemia, cerebrovascular
accident,andembolismamongtheMEC-onlytreatedgroup;
arterial thromboembolic events with chest pain among
the HEC/MEC combined chemotherapy groups; arterial
thromboembolic events without chest pain, hypertension,
and venous thromboembolic events in the HEC-only treated
group. While there were some CVD-related events that
occurred at a higher frequency among aprepitant users
compared to nonusers, the absolute number of events was
small, and most events were either similar across the two
groups or higher in the nonaprepitant user group. In
particular, in the MEC-only group, with its large numbers
of users and nonusers, arterial disorder was higher among
aprepitant users but the occurrence of all other events was
either similar or lower among aprepitant users compared to
nonusers. This may be explained by the fact that nonusers
were more likely than users to be older and have a prior
history of cardiovascular disease.
Aprepitant is a substrate and dose-dependent inhibitor
and inducer of the cytochrome P4503A4 (CYP3A4) isoen-
zyme, and drugs metabolized by CYPA34 can have a
potential drug interaction with aprepitant [19].For example,
cyclophosphamide is an anticancer agent that is metabolized
to its active metabolites by CYPA34 [10] and is also
associatedwithcardiacsideeﬀectssuchasacuteheartfailure,
pericardial eﬀusion, and arrhythmia [7]. Coadministration
with aprepitant causes a decrease in plasma concentrations
of the active metabolites of cyclophosphamide by 5% [20], a
level which may not be clinically signiﬁcant [10].
Some 5-HT3 RA antiemetics (e.g., dolasetron, granis-
etron and ondansetron) have been associated with revers-
ible, clinically insigniﬁcant changes to electrocardiographic
(ECG) parameters (i.e., PR, QTS, QT, and JT intervals) [21],
and their coadministration could have a diluting or enhanc-
ing eﬀect on the occurrence of cardiovascular events.
As with all administrative databases, the claims data
collected were not designed for research purposes, and, thus,
are limited in scope and lack detailed clinical information
available in medical records, such as ECG readings and lab
data on MI-induced elevations of troponin, and so forth.
A claim may represent a condition to be ruled out rather
than diagnosis of the condition, itself. Discharge diagnosis
for the identiﬁcation of cardiovascular and thromboembolic
events can have several sources of error, including variationJournal of Cancer Epidemiology 7
Table 5: Chemotherapeutic agents according to HEC or MEC status.
HEC or MEC Chemotherapeutic agent Strength NDC or J-code
Oral
MEC (low) Arsenic 10MG/10ML 60553011110
MEC (low) Arsenic 10MG/10ML 63459060010
MEC (low) Carboplatin 50MG/0ML 15321030
MEC (low) Carboplatin 150MG/10ML 15321130
MEC (low) Carboplatin 450MG/40ML 15321230
MEC (low) Carboplatin 50MG 15321330
MEC (low) Carboplatin 150MG 15321430
MEC (low) Carboplatin 450MG 15321530
MEC (low) Carboplatin 10MG/ML 591333712
MEC (low) Carboplatin 10MG/ML 591333889
MEC (low) Carboplatin 10MG/ML 703324411
MEC (low) Carboplatin 10MG/ML 703324611
MEC (low) Carboplatin 10MG/ML 703324811
MEC (low) Carboplatin 10MG/ML 703324911
MEC (low) Carboplatin 50MG 703326401
MEC (low) Carboplatin 150MG 703326601
MEC (low) Carboplatin 450MG 703326801
MEC (low) Carboplatin 10MG/ML 703424401
MEC (low) Carboplatin 10MG/ML 703424601
MEC (low) Carboplatin 10MG/ML 703424801
MEC (low) Carboplatin 10MG/ML 10019091202
MEC (low) Carboplatin 10MG/ML 10019091203
MEC (low) Carboplatin 50MG 10019091501
MEC (low) Carboplatin 150MG 10019091601
MEC (low) Carboplatin 450MG 10019091701
MEC (low) Carboplatin 50MG 50111096576
MEC (low) Carboplatin 150MG 50111096676
MEC (low) Carboplatin 450MG 50111096776
MEC (low) Carboplatin 50MG 55390015001
MEC (low) Carboplatin 150MG 55390015101
MEC (low) Carboplatin 450MG 55390015201
MEC (low) Carboplatin 10MG/ML 55390015301
MEC (low) Carboplatin 10MG/ML 55390015401
MEC (low) Carboplatin 10MG/ML 55390015501
MEC (low) Carboplatin 10MG/ML 61703033918
MEC (low) Carboplatin 10MG/ML 61703033922
MEC (low) Carboplatin 10MG/ML 61703033950
MEC (low) Carboplatin 10MG/ML 61703033956
MEC (low) Carboplatin 150MG 63323016721
MEC (low) Carboplatin 450MG 63323016800
MEC (low) Carboplatin 10MG/ML 63323016905
MEC (low) Carboplatin 10MG/ML 63323016915
MEC (low) Carboplatin 10MG/ML 63323016945
MEC (low) Carboplatin 10MG/ML 63323017245
MEC (low) Cyclophosphamide 100MG 13560693
MEC (low) Cyclophosphamide 200MG 13561693
MEC (low) Cyclophosphamide 500MG 13562693
MEC (low) Cyclophosphamide 500MG 150502418 Journal of Cancer Epidemiology
Table 5: Continued.
MEC (low) Cyclophosphamide 50MG 15050301
HEC or MEC Chemotherapeutic agent Strength NDC or J-code
MEC (low) Cyclophosphamide 50MG 15050302
MEC (low) Cyclophosphamide 25MG 15050401
MEC (low) Cyclophosphamide 100MG 15053941
MEC (low) Cyclophosphamide 200MG 15054641
MEC (low) Cyclophosphamide 500MG 15054741
MEC (low) Cyclophosphamide 25MG 54412925
MEC (low) Cyclophosphamide 50MG 54413025
MEC (low) Cyclophosphamide 25MG 54808925
MEC (low) Cyclophosphamide 50MG 54813025
MEC (low) Cyclophosphamide 500MG 10019095501
MEC (low) Cytarabine 1GM 9329501
MEC (low) Cytarabine 1GM 703519401
MEC (low) Cytarabine 1GM 55390013301
MEC (low) Cytarabine 1GM 55390080801
MEC (low) Daunorubicin 20MG 703503203
MEC (low) Daunorubicin 20MG/4ML 55390010810
MEC (low) Daunorubicin 20MG 55390028110
MEC (low) Daunorubicin 2MG/ML 56146030101
MEC (low) Daunorubicin 2MG/ML 61958030101
MEC (low) Doxorubicin 20MG 13109691
MEC (low) Doxorubicin 20MG 13109694
MEC (low) Doxorubicin 20MG/10ML 13114691
MEC (low) Doxorubicin 20MG/10ML 13114694
MEC (low) Doxorubicin 20MG/10ML 13124691
MEC (low) Doxorubicin 50MG/20ML 13115679
MEC (low) Doxorubicin 50MG/20ML 13125679
MEC (low) Doxorubicin 50MG 186153101
MEC (low) Doxorubicin 50MG 10019092102
MEC (low) Doxorubicin 50MG 55390023301
MEC (low) Doxorubicin 50MG 55390024301
MEC (low) Epirubicin 2MG/ML 9509101
MEC (low) Epirubicin 2MG/ML 9509301
MEC (low) Epirubicin 50MG 61703034735
MEC (low) Idarubicin 5MG 13250694
MEC (low) Idarubicin 20MG 13252686
MEC (low) Idarubicin 1MG/ML 13253678
MEC (low) Idarubicin 1MG/ML 13255667
MEC (low) Idarubicin 1MG/ML 13259691
MEC (low) Ifosfamide 1GM 15055605
MEC (low) Ifosfamide 1GM 15055611
MEC (low) Ifosfamide 1GM 15055641
MEC (low) Ifosfamide 3GM 15055741
MEC (low) Ifosfamide 5GM/3GM 703410048
MEC (low) Ifosfamide 1GM 63323014210
MEC (low) Irinotecan 20MG/ML 9752901
MEC (low) Irinotecan 20MG/ML 9752902
MEC (low) Pentostatin 10MG 62701080001
MEC (low) Temozolomide 5MG 85124801Journal of Cancer Epidemiology 9
Table 5: Continued.
MEC (low) Temozolomide 5MG 85124802
HEC or MEC Chemotherapeutic agent Strength NDC or J-code
MEC (low) Temozolomide 5MG 85124803
MEC (low) Temozolomide 20MG 85124401
MEC (low) Temozolomide 20MG 85124402
MEC (low) Temozolomide 250MG 85125201
MEC (low) Temozolomide 250MG 85125202
MEC (low) Temozolomide 100MG 85125901
MEC (low) Temozolomide 100MG 85125902
MEC (low) Temozolomide 100MG 85136601
MEC (low) Temozolomide 100MG 85136602
MEC (low) Temozolomide 250MG 85141701
MEC (low) Temozolomide 140MG 85142501
MEC (low) Temozolomide 140MG 85142502
MEC (low) Temozolomide 180MG 85143001
MEC (low) Temozolomide 180MG 85143002
MEC (low) Temozolomide 20MG 85151901
MEC (low) Temozolomide 20MG 85151902
MEC (low) Temozolomide 20MG 54868414205
MEC (low) Temozolomide 20MG 54868414206
MEC (low) Temozolomide 5MG 54868534801
MEC (low) Temozolomide 100MG 54868535002
MEC (low) Temozolomide 250MG 54868535400
MEC (high) Carmustine 100MG 15301238
MEC (high) Carmustine 100MG 15301297
MEC (high) Cisplatin 50MG/50ML 15322022
MEC (high) Cisplatin 50MG/50ML 15322097
MEC (high) Cisplatin 1MG/ML 703574711
MEC (high) Cisplatin 1MG/ML 703574811
MEC (high) Cisplatin 1MG/ML 10019091001
MEC (high) Cisplatin 1MG/ML 10019091002
MEC (high) Cisplatin 50MG/50ML 55390011250
MEC (high) Cisplatin 50MG/50ML 55390041450
MEC (high) Cisplatin 1MG/ML 63323010351
MEC (high) Cisplatin 1MG/ML 63323010364
MEC (high) Cisplatin 1MG/ML 63323010365
MEC (high) Cyclophosphamide 1GM 13563670
MEC (high) Cyclophosphamide 1GM 15050541
MEC (high) Cyclophosphamide 1GM 15054812
MEC (high) Cyclophosphamide 1GM 15054841
MEC (high) Cyclophosphamide 1GM 10019095601
MEC (high) Cytarabine 2GM 55390013401
MEC (high) Cytarabine 2GM 55390080901
MEC (high) Cytarabine 2000MG/20ML 61703031922
MEC (high) Cytarabine 2000MG/20ML 61703031922
MEC (high) Dactinomycin 0.5MG 6329822
MEC (high) Dactinomycin 0.5MG 67386081155
MEC (high) Doxorubicin 200MG/100ML 13116683
MEC (high) Doxorubicin 75MG/37.0ML 13117687
MEC (high) Etoposide 500MG/20ML 1530612010 Journal of Cancer Epidemiology
Table 5: Continued.
MEC (high) Etoposide 1GM/50ML 15306220
HEC or MEC Chemotherapeutic agent Strength NDC or J-code
MEC (high) Etoposide 500MG/20ML 55390029201
MEC (high) Etoposide 1000MG/50ML 55390029301
MEC (high) Etoposide 500MG/20ML 55390049201
MEC (high) Etoposide 1000MG/50ML 55390049301
MEC (high) Melphalan 2MG 81004535
MEC (high) Melphalan 2MG 173004535
MEC (high) Melphalan 50MG 173013093
MEC (high) Melphalan 50MG 173013093
MEC (high) Melphalan 2MG 54868433901
MEC (high) Melphalan 2MG 54868433902
MEC (high) Melphalan 2MG 59572030250
MEC (high) Methotrexate 1GM 55390014301
MEC (high) Methotrexate 1000MG/40ML 63323012140
MEC (high) Methotrexate 1GM 63323012250
MEC (high) Methotrexate 1GM 66479013929
MEC (high) Procarbazine 50MG 4005301
MEC (high) Procarbazine 50MG 54482005301
HEC Cisplatin 100MG/100ML 15322122
HEC Cisplatin 100MG/100ML 55390011299
HEC Cyclophosphamide 2GM 13564670
HEC Cyclophosphamide 2GM 15050641
HEC Cyclophosphamide 2GM 15054941
HEC Cyclophosphamide 2GM 10019095701
HEC Dacarbazine 200MG 26815120
HEC Dacarbazine 200MG 703507501
HEC Dacarbazine 200MG 703507503
HEC Dacarbazine 200MG 55390009010
HEC Dacarbazine 200MG 61703032722
HEC Dacarbazine 100MG 63323012710
HEC Dacarbazine 200MG 63323012820
HEC Mechlorethamine 10MG 6775331
HEC Mechlorethamine 10MG 67386091151
HEC Streptozocin 1GM 9084401
HEC Streptozocin 1GM 703463601
Injectables
MEC (low) Cyclophosphamide; oral 25MG J8530
MEC (low) Injection, arsenic trioxide 1MG J9017
MEC (low) Cyclophosphamide 100MG J9070
MEC (low) Cyclophosphamide 200MG J9080
MEC (low) Cyclophosphamide 500MG J9090
MEC (low) Cyclophosphamide, lyopholized 100MG J9093
MEC (low) Cyclophosphamide, lyopholized 200MG J9094
MEC (low) Cyclophosphamide, lyopholized 500MG J9095
MEC (low) Injection, epirubicin HCL 2MG J9178
MEC (low) Injection, irinotecan 20MG J9206
MEC (low) Injection, ifosfamide 1 GM J9208Journal of Cancer Epidemiology 11
Table 5: Continued.
HEC or MEC Chemotherapeutic agent Strength NDC or J-code
MEC (low) Injection, idarubicin hydrochloride 5MG J9211
MEC (low) Injection, mitoxantrone hydrochloride Per 5MG J9293
MEC (low) Lomustine, oral 10MG S0178
MEC (high) Injection, carboplatin 50MG J9045
MEC (high) Injection, carmustine 100MG J9050
MEC (high) Cisplatin, powder or solution PER 10MG J9060
MEC (high) Cyclophosphamide 1.0 GM J9091
MEC (high) Cyclophosphamide, lyophilized 1.0 GM J9096
MEC (high) Injection, dactinomycin 0.5MG J9120
MEC (high) Injection, melphalan hydrochloride 50MG J9245
MEC (high) Pracarbazine hydrochloride, oral 50MG S0182
HEC Cisplatin 50MG J9062
HEC Cyclophosphamide 2.0 GM J9092
HEC Cyclophosphamide, lyophilized 2.0 GM J9097
HEC Dacarbazine 100MG J9130
HEC Dacarbazine 200MG J9140
HEC Injection, mechlorethamine hydrochloride
(nitrogen mustard) 10MG J9230
HEC Injection, streptozocin 1GM J9320
MEC (low): moderately emetogenic chemotherapy associated with 30–60% of patients having emesis, MEC (high): moderately emetogenic chemotherapy
associated with 60–90% of patients having emesis, HEC: highly emetogenic chemotherapy associated with >90% of patients having emesis.
in coding procedures, coding errors, incomplete coding,
lack of speciﬁcity in available codes, and error in clinical
diagnosis [22]. Misclassiﬁcation of outcomes could lead to
biased results. Nevertheless, the usefulness of claims data for
certain CVD events has been assessed by other investiga-
tors. For example, a validation study of claim codes from
a commercial insurance claims database, similar to IMPACT,
against the gold standard medical records, showed a positive
predictive value of 88% for both myocardial infarction and
ischemic stroke [23].
This was a high-level analysis performed to provide over-
all background rates in a population of cancer patients
similar to those under study in our clinical development
program. It was not designed to draw causal inferences in
diﬀerences between users of aprepitant and nonusers. The
decisionwhethertotreatwithaprepitantmostlikelydepends
on many factors, such as the ability to pay for medi-
cations, physician experience, emetogenic potential of the
chemotherapeuticagent,drug-druginteractions,andwheth-
er treatment is for acute or delayed CINV [24, 25]. We did
not attempt to unmask or correct for potential channeling
bias, nor did we consider other possible confounding factors
between the aprepitant user and nonuser groups, including
drug severity and comorbidity. Our comparisons did not
take into account possible confounding due to drug-
druginteractionswithspeciﬁccardiotoxicchemotherapeutic
agents or other coadministered antiemetics. We did not ac-
count for chemotherapeutic drug dosages and did not have
adequate sample size for assessing eﬀects among individual
cycles of chemotherapy. As a next step, we would have
corrected for as many of these shortcomings as possible in
a subsequent, more rigorous pharmacoepidemiology study
had our clinical development program advanced.
Despite these limitations, this analysis provided a “real
world” clinical practice baseline picture of the frequency
of CVD-related events that occur during use of highly or
moderately emetogenic chemotherapy, serving as a useful
benchmark for safety signals identiﬁed during one of our
clinical trial programs. Results should also serve for future
supportive care studies. The preliminary information on ex-
periences of the aprepitant antiemetic group compared to
nonusers was helpful but should be interpreted cautiously.
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